185P - Prognostic impact of tumor location and use of monoclonal antibodies in patients with metastatic colorectal cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Masato Nakamura
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors M. Nakamura, T. Onikubo, K. Nakamura, K. Tauchi
  • Aizawa Comprehensive Cancer Center, Aizawa Hospital, 390-8510 - Matsumoto/JP

Abstract

Background

Combination of cytotoxic agents and monoclonal antibodies (mAbs; bevacizumab, cetuximab and panitumumab) are recommended as first line therapy for metastatic colorectal cancer (mCRC) in guidelines. On the other hand, recent clinical data suggests that the location of colorectal tumor (i.e. proximal vs. distal colon) may have prognostic value and also have predictive impact for the effect of mAbs. To investigate the correlations among tumor location, use of mAb in first line chemotherapy and overall survival (OS), we conducted a retrospective analysis.

Methods

Patients who underwent first line therapy with doublet or triplet cytotoxic drugs for mCRC in our hospital are eligible for this study. Cecum and ascending colon were categorized as “right-side”. Descending colon, sigmoidal colon and rectum were categorized as “left-side”. Transverse colon was excluded from this analysis. In case of multicentric mCRC, the patient was included to the group which more advanced tumor was existed.

Results

From March 2006 to April 2016, 279 mCRC patients were enrolled in this study. The median duration of follow-up was 61.6 months (mos). M/F=170/109. Median age was 66 (31-89). The number of oxaliplatin based regimen, irinotecan based regimen and FOLFOXIRI was 257, 19 and 3, respectively. In 169 patients, mAbs were used in first line therapy (bevacizumab 112, anti-EGFR mAb 57). OS of all eligible patients was 31.5 mos. OS with mAbs was statistically longer than without mAbs (34.3 mos v.s. 27.8 mos; p = 0.006). There was no difference between bevacizumab and anti-EGFR mAb (33.4mos v.s.35.0mos, p = 0.913). OS of left-side was statistically longer than right-side (35.9 mos v.s. 19.3 mos; p 

Conclusions

In mCRC, tumor location has prognostic impact. Adding mAbs to first line chemotherapy significantly improved OS, and the effect was observed especially in left-side.

Clinical trial indentification

Legal entity responsible for the study

Aizawa Hospital

Funding

Aizawa hospital

Disclosure

All authors have declared no conflicts of interest.